Acquisition of verona by msd approved by the high court of justice of england and wales

London and raleigh, n.c., oct. 06, 2025 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on july 8, 2025 relating to its proposed acquisition by msd (tradename of merck & co., inc., rahway, n.j., usa), known as merck in the u.s. and canada, through a wholly owned subsidiary or a nominee, today announced that the high court of justice of england and wales has approved the proposal for msd to acquire verona pharma for $107 per american depository share (ads), each of which represents eight verona pharma ordinary shares, for a total transaction value of approximately $10 billion (the “transaction”).
VRNA Ratings Summary
VRNA Quant Ranking